Citable company snapshot
Merck & Co.'s latest SEC-sourced 2026-03-31 period shows $16.29B in revenue and $-4.24B in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| xbrl:Revenues | Mar 31, 2026 | $16.29B | $16.40B | -0.7% |
| xbrl:NetIncomeLoss | Mar 31, 2026 | $-4.24B | $2.96B | -243.1% |
| xbrl:NetCashProvidedByUsedInOperatingActivities | Mar 31, 2026 | $3.92B | $2.86B | +37.1% |
| Free Cash Flow (computed) | Mar 31, 2026 | $2.93B | $1.82B | +60.5% |
Source: SEC EDGAR XBRL; period Mar 31, 2026; filed May 4, 2026; accession 0001628280-26-029802.
Continue research
Follow same-sector companies and source explainers connected to the financials view.
A factual guide to free cash flow — how it is built from the cash flow statement, why presentations differ, and how Aerarium Research shows the source.
A factual guide to working capital, current assets, current liabilities, and the operating cash cycle.
A factual guide to stock-based compensation, how it appears in company filings, and why it connects cash flow to share count.
A factual guide to goodwill, intangible assets, acquisitions, and impairment charges in company financial statements.
